Mimetogen Pharmaceuticals Inc. Appoints Chief Medical Officer
News Jan 06, 2012
It was previously announced that MIM-D3, a small molecule TrkA agonist, had successfully completed a 150-patient, multi-center Phase 2 trial for the treatment of dry eye, demonstrating significant improvements in signs and symptoms of the disease and an excellent safety profile.
"MIM-D3 is an exciting molecule with a unique mechanism of action that addresses several of the key causes and sequelae of dry eye disease," said Kim Brazzell, Ph.D., Chief Medical Officer. "This product differentiation and the strength of the Phase 2 data package, with significant improvements in both signs and symptoms of the disease, position MIM-D3 as an important entrant to the blockbuster field of dry eye. I look forward to working with the team at Mimetogen to advance MIM-D3 into a pivotal program."
"Dr. Brazzell's leadership in the successful development of a number of FDA-approved ophthalmic products is ideally suited to the significant potential of the MIM-D3 program and we look forward to his contributions to Mimetogen and the development of MIM-D3," said Garth Cumberlidge, Ph.D., President and Chief Executive Officer of Mimetogen.
Dr. Brazzell brings more than 20 years of experience in the ophthalmic pharmaceutical industry to Mimetogen. Previously, he held several executive positions at Inspire Pharmaceuticals, including Executive Vice President, Medical and Scientific Affairs, Executive Vice President and Head, Ophthalmology Business and Senior Vice President of Ophthalmic Research and Development. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics. He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne(R), Zaditor(R), RESCULA(R) and Betoptic S(R). In addition to managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics, while serving as their Vice President, R&D, and served as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in pharmacy and a Ph.D. in pharmaceutical sciences from the University of Kentucky.
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019